189 related articles for article (PubMed ID: 28766964)
21. Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast.
Barnes NL; Khavari S; Boland GP; Cramer A; Knox WF; Bundred NJ
Clin Cancer Res; 2005 Mar; 11(6):2163-8. PubMed ID: 15788662
[TBL] [Abstract][Full Text] [Related]
22. HER2 as a prognostic factor in breast cancer.
Ménard S; Fortis S; Castiglioni F; Agresti R; Balsari A
Oncology; 2001; 61 Suppl 2():67-72. PubMed ID: 11694790
[TBL] [Abstract][Full Text] [Related]
23. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast.
Latta EK; Tjan S; Parkes RK; O'Malley FP
Mod Pathol; 2002 Dec; 15(12):1318-25. PubMed ID: 12481013
[TBL] [Abstract][Full Text] [Related]
24. [Does molecular biology play any role in ductal carcinoma in situ?].
Sakr RA
Gynecol Obstet Fertil; 2013 Jan; 41(1):45-53. PubMed ID: 23286959
[TBL] [Abstract][Full Text] [Related]
25. Loss of androgen receptor associated protein 70 (ARA70) expression in a subset of HER2-positive breast cancers.
Kollara A; Kahn HJ; Marks A; Brown TJ
Breast Cancer Res Treat; 2001 Jun; 67(3):245-53. PubMed ID: 11561770
[TBL] [Abstract][Full Text] [Related]
26. Is there a low-grade precursor pathway in breast cancer?
King TA; Sakr RA; Muhsen S; Andrade VP; Giri D; Van Zee KJ; Morrow M
Ann Surg Oncol; 2012 Apr; 19(4):1115-21. PubMed ID: 21935747
[TBL] [Abstract][Full Text] [Related]
27. A Case Report of
Lee M; Lee J; Lee A; Kang J
Int J Surg Pathol; 2023 Aug; 31(5):801-804. PubMed ID: 36437641
[TBL] [Abstract][Full Text] [Related]
28. ASO Author Reflections: Active Surveillance for Ductal Carcinoma In Situ (DCIS).
Oseni TO; Bahl M
Ann Surg Oncol; 2020 Oct; 27(11):4466-4467. PubMed ID: 32440718
[No Abstract] [Full Text] [Related]
29. [Analysis of HER2 gene amplification and its protein expression in 165 cases of breast carcinoma: comparison of chromogenic in-situ hybridization and immunohistochemistry].
Shen DH; Wang FH; Yu YZ
Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):457-60. PubMed ID: 17845758
[TBL] [Abstract][Full Text] [Related]
30. [Prognostic factors of breast cancer].
Tang P; Wei B; Yang WJ; Liu YS; Bu H
Zhonghua Bing Li Xue Za Zhi; 2011 Feb; 40(2):73-6. PubMed ID: 21426799
[No Abstract] [Full Text] [Related]
31. Field cancerization in mammary carcinogenesis - Implications for prevention and treatment of breast cancer.
Rivenbark AG; Coleman WB
Exp Mol Pathol; 2012 Dec; 93(3):391-8. PubMed ID: 23142414
[TBL] [Abstract][Full Text] [Related]
32. HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ.
Sharma A; Koldovsky U; Xu S; Mick R; Roses R; Fitzpatrick E; Weinstein S; Nisenbaum H; Levine BL; Fox K; Zhang P; Koski G; Czerniecki BJ
Cancer; 2012 Sep; 118(17):4354-62. PubMed ID: 22252842
[TBL] [Abstract][Full Text] [Related]
33. Restoring anti-oncodriver Th1 responses with dendritic cell vaccines in HER2/neu-positive breast cancer: progress and potential.
De La Cruz LM; Nocera NF; Czerniecki BJ
Immunotherapy; 2016 Oct; 8(10):1219-32. PubMed ID: 27605070
[TBL] [Abstract][Full Text] [Related]
34. Exosomal pMHC-I complex targets T cell-based vaccine to directly stimulate CTL responses leading to antitumor immunity in transgenic FVBneuN and HLA-A2/HER2 mice and eradicating trastuzumab-resistant tumor in athymic nude mice.
Wang L; Xie Y; Ahmed KA; Ahmed S; Sami A; Chibbar R; Xu Q; Kane SE; Hao S; Mulligan SJ; Xiang J
Breast Cancer Res Treat; 2013 Jul; 140(2):273-84. PubMed ID: 23881522
[TBL] [Abstract][Full Text] [Related]
35. HER2 protein overexpression in non-amplified ductal carcinoma in situ: quality issue or transcription mechanisms gone awry?
Lambein K; Libbrecht L; Galant C; Van Bockstal MR
Histopathology; 2019 Mar; 74(4):666-668. PubMed ID: 30480328
[No Abstract] [Full Text] [Related]
36. ASO Author's Reflections: Are Genomic Assays Informing the Management of Ductal Carcinoma in situ as They Have for Invasive Breast Cancer?
Piltin MA; Boughey JC
Ann Surg Oncol; 2021 Aug; 28(8):4304-4305. PubMed ID: 33527230
[No Abstract] [Full Text] [Related]
37. Activated c-SRC in ductal carcinoma in situ correlates with high tumour grade, high proliferation and HER2 positivity.
Wilson GR; Cramer A; Welman A; Knox F; Swindell R; Kawakatsu H; Clarke RB; Dive C; Bundred NJ
Br J Cancer; 2006 Nov; 95(10):1410-4. PubMed ID: 17060931
[TBL] [Abstract][Full Text] [Related]
38. Some DCIS is different molecularly from DCIS with co-existing IDC.
Steinman S; Bourne P; Yang Q; Tang P; Wang J
Breast J; 2008; 14(1):122-3. PubMed ID: 18186882
[No Abstract] [Full Text] [Related]
39. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.
Castro NP; Osório CA; Torres C; Bastos EP; Mourão-Neto M; Soares FA; Brentani HP; Carraro DM
Breast Cancer Res; 2008; 10(5):R87. PubMed ID: 18928525
[TBL] [Abstract][Full Text] [Related]
40. HER2 overexpression of breast cancers in Hong Kong shows good concordance with HER2 amplification by fluorescence in-situ hybridisation study.
Chan JK; Tsang WY; Lo ES; Wong MC
Hong Kong Med J; 2008 Aug; 14(4):333; author reply 334. PubMed ID: 18685172
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
